Literature DB >> 15990258

Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube.

D Messaouik1, V Sautou-Miranda, S Bagel-Boithias, J Chopineau.   

Abstract

Patients in intensive care often develop stress-induced ulcers. As a preventive measure, proton pump inhibitors (PPIs) are administered by nasogastric tube. However, some PPIs can block the tube. The aim of this study was to compare the behaviour of three PPIs (omeprazole, lanzoprazole and esomeprazole) during the transit of the granules through the tube and to optimise their modes of administration. For each IPP, the experiment was designed to study the influence of four variables: the tube material (silicone or polyurethane), the solvent used to dilute the granules (water or apple juice), the mode of administration (in two or three doses) and the rinse volume (10 or 20 ml). We counted the granules before transit and at the tube outlet, and assayed the active drug ingredient by UV spectrometry. The assay showed complete transit of esomeprazole through the tube, but average losses of omeprazole and lanzoprazole of 39 and 33%, respectively, were observed. No significant improvement was obtained by the variables 'diluent' and 'mode of administration'. The variable 'rinse' had a significant influence. For lanzoprazole, a polyurethane tube allowed recovery of on average 86% of the active ingredient. Esomeprazole is thus the choice PPI for the treatment of patients by nasogastric tube. Using a polyurethane tube and a rinse volume of 20 ml, the administration of lanzoprazole by tube can be considered. Use of omeprazole is not recommended because none of the modes of administration tested ensured that a sufficient concentration of active ingredient reached the stomach.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990258     DOI: 10.1016/j.ijpharm.2005.04.034

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  8 in total

1.  In vitro study of esomeprazole sachet suspension administered via enteral feeding tubes.

Authors:  Paul Stewart; Natalie Dayneka; Sylvain Grenier; Carolyn Stewart; Lise Beadow; Gerry Joseph; David Mack; Régis Vaillancourt
Journal:  Can J Hosp Pharm       Date:  2009-01

2.  Plasma levels of oral risperidone during enteral nutrition in a pregnant schizophrenic patient.

Authors:  Giovanni Oriolo; Lucila Barbosa; Maria Luisa Imaz; Luisa Garcia; Sergi Borrego; Eduard Parellada
Journal:  Ther Adv Psychopharmacol       Date:  2015-04

3.  In Vitro Evaluation of Eslicarbazepine Delivery via Enteral Feeding Tubes.

Authors:  Kristin Reindel; Fang Zhao; Susan Hughes; Vivek S Dave
Journal:  Hosp Pharm       Date:  2017-09-25

4.  In vitro Approaches to Support Bioequivalence and Substitutability of Generic Proton Pump Inhibitors via Nasogastric Tube Administration.

Authors:  Ping Ren; Minglei Cui; Om Anand; Li Xia; Zhuojun J Zhao; Dajun Sun; Trueman Sharp; Dale P Conner; John Peters; Wenlei Jiang; Ethan Stier; Xiaojian Jiang
Journal:  AAPS J       Date:  2017-09-06       Impact factor: 4.009

5.  In Vitro Evaluation of Nasogastric Tube Delivery Performance of Esomeprazole Magnesium Delayed-Release Capsules.

Authors:  Alicia Hoover; Dajun Sun; Hong Wen; Wenlei Jiang; Minglei Cui; Xiaojian Jiang; David Keire; Changning Guo
Journal:  J Pharm Sci       Date:  2017-04-15       Impact factor: 3.534

Review 6.  Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review.

Authors:  Mark P Tighe; Nadeem A Afzal; Amanda Bevan; R Mark Beattie
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

7.  Accuracy of hydrocortisone dose administration via nasogastric tube.

Authors:  Eleni Daniel; Martin J Whitaker; Brian Keevil; Jerry Wales; Richard J Ross
Journal:  Clin Endocrinol (Oxf)       Date:  2018-11-09       Impact factor: 3.478

8.  Appropriateness of administration of nasogastric medication and preliminary intervention.

Authors:  Ling-Ling Zhu; Ling-Cheng Xu; Hui-Qin Wang; Jing-Fen Jin; Hua-Fen Wang; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2012-11-20       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.